WHO ICTRP trial
Phase IIa trial of MK0646 Tx in combo w/ Irinotecan vs Cetuximab and Irinotecan…
EUCTR2012-000317-36-ES · EU Clinical Trials Register · Not Recruiting
Key facts
| Trial ID | EUCTR2012-000317-36-ES |
|---|---|
| Public title | Phase IIa trial of MK0646 Tx in combo w/ Irinotecan vs Cetuximab and Irinotecan for mRC patients |
| Scientific title | A Phase IIA Open Label, Adaptive, Randomized Clinical Trial of Dalotuzumab (MK-0646) Treatment in Combination with Irinotecan Versus Cetuximab and Irinotecan for Patients with Metastatic Rectal Cancers (mRC) Expressing High IGF-1/Low IGF-2 Levels - Phase IIa trial of MK0646 Tx in combo w/ Irinotecan… |
| Primary sponsor | Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. |
| Registry | EU Clinical Trials Register |
| Recruitment status | Not Recruiting |
| Study type | Interventional clinical trial of medicinal product |
| Countries | United States;Taiwan;Spain;Korea, Democratic People's Republic of;Chile;United Kingdom;Brazil;Belgium;Peru;Australia;Denmark;New Zealand;Sweden |
| Conditions | rectal cancer MedDRA version: 14.1 Level: PT Classification code 10038038 Term: Rectal cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) ;Therapeutic area: Diseases [C] - Cancer [C04] |
| Interventions | Product Name: dalotuzumab Product Code: MK-0646 Pharmaceutical Form: Solution for infusion INN or Proposed INN: dalotuzumab CAS Number: 1005389-60-5 Current Sponsor code: MK-0646 Concentration unit: mg/ml milligram(s)/millilitre… |
| Registration date | Apr 26, 2012 |
| Target size | 70 |
| Secondary IDs | 0646-025 |
| Registry page | clinicaltrialsregister.eu |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: